NEWS RELEASE

Teijin Receives Additional Approval in Japanfor Merz’s Xeomin® Botulinum Toxin Type AFrankfurt, Germany, June 23, 2021 --- Merz Therapeutics, a business of the Merz Groupand a leader in the field of neurotoxins, and Teijin Pharma Limited, the core company of theTeijin Group’s healthcare business, jointly announced today that Teijin Pharma has been
granted additional approval by Japan’s Ministry of Health, Labor and Welfare (MHLW) tomarket Xeomin® (incobotulinumtoxinA) for intramuscular injection in 50, 100 or 200 units forthe treatment of lower limb spasticity.
Lower limb spasticity is a symptom of upper motor neuron syndrome, which is expressed
mainly by increased muscle tone of limbs and the hyperexcitability of the stretch reflex as asequela of stroke. The main symptoms are difficulty in normal walking and increased risk offalling due to trunk instability, complicating or impeding activities in daily life. Conventional
treatment of lower limb spasticity includes physical rehabilitation and the use of oral muscle
relaxants or neuromuscular blockers such as botulinum toxin type A.
Stefan Brinkmann, CEO Merz Therapeutics: “The extended approval marks an importantmilestone for Merz Therapeutics and is the result of our close and trustful partnership withTeijin Pharma in Japan. We wish our partner a successful introduction of this important
spasticity indication to the Japanese doctors and patients.”
Dr. Stefan Albrecht, Senior Vice President Merz Therapeutics Global R&D: “This label
extension in Japan is another outstanding example for the benefits Xeomin® offers to many
post-stroke spasticity patients. Physicians now have the choice to treat lower and upper limb
spasticity, also in combination and with the flexibility to apply the individual dosage as needed.
We are proud of this achievement and in particular of the excellent collaboration with ourpartner Teijin.”
Teijin Pharma President Ichiro Watanabe said: “Teijin Pharma provides various
pharmaceuticals including for osteoporosis treatment and medical devices such as a sonicaccelerated fracture healing system for patients suffering from musculoskeletal diseases. In
response to demographic change and increased health consciousness, we are launchingeffective new drugs and solutions, including to realize more sustainable societies. Teijin
Pharma continues to contribute to enhancing the quality of life (QOL) of patients by providing
new treatment options for diseases with high unmet needs.”
Xeomin® is effective in treating peripheral cholinergic nerve endings by weakening thecontraction of voluntary muscles, and it relieves muscle tone by inhibiting the release of aneurotransmitter called acetylcholine. The highly purified neurotoxin, the only active
ingredient in Xeomin®, is made by removing complexing proteins from botulinum toxin typeA, which is produced by Clostridium botulinum, using purification technology developed byMerz Pharma GmbH & Co. KGaA. The lack of complexing proteins enables Xeomin® toreduce the production of neutralizing antibodies capable of lowering efficacy. A significant

improvement in the modified ashworth scale (MAS) score for the plantar flexors wasobserved in phase-III clinical trials in Japan.
Xeomin® is being distributed by Merz Pharmaceuticals GmbH in more than 70 countries totreat patients with upper limb spasticity, cervical dystonia, blepharospasm and hemifacial
spasm or hypersalivation. Teijin Pharma signed an exclusive license and co-development
agreement for Xeomin® in Japan with Merz in 2017, and launched exclusive sales of Xeomin®
in December 2020 after receiving approval granted by Japan’s Ministry of Health, Labor andWelfare (MHLW). The newly received additional approval for partial changes in the obtained
approval based on the phase-III clinical trials conducted by Merz in Japan.

About Xeomin®
Xeomin® 50 units for intramuscular injection
Brand name

Xeomin®100 units for intramuscular injection
Xeomin® 200 units for intramuscular injection

NonproprietarynameincobotulinumtoxinA

Dosage form

Injection (vial)

Indication

Lower limb spasticity(for the treatment of lower limb spasticity)
In general, for adults, Xeomin® should be injected into multiple tonic muscles.* Themaximum dose per administration is 400 units, however, the dose should beappropriately reduced to the minimum depending on the type and number ofDosage andtargeted tonic muscles. Repeated doses are permissible if the effect of a previous

administrationdose diminishes. The dosing interval should be 12 weeks or longer but may be
shortened to 10 weeks depending on the symptoms.
*Tonic muscles: gastrocnemius (medial head, lateral head), soleus muscle, tibialis
posterior muscle, flexor digitorum longus muscle, etc.

Xeomin® is the registered trademark of Merz Pharma GmbH & Co. KGaA.

About Merz Therapeutics
Merz Therapeutics, a business of Merz Pharmaceuticals GmbH, is dedicated toimproving the lives of patients around the world. With its relentless research,development, and culture of innovation, Merz Therapeutics strives to serve unmet patientneeds and realize better outcomes. Merz Therapeutics seeks to address the uniqueneeds of people who suffer from movement disorders, neurological conditions, liverdisease, and other health conditions that severely impact patients’ quality of life. Merz
Therapeutics is headquartered in Frankfurt, Germany and is represented in more than
90 countries, with a North America affiliate based in Raleigh, North Carolina. Merz
Pharmaceuticals GmbH is part of the Merz Group, a privately held, family-owned
company that has dedicated more than 110 years to developing innovations that meetpatient and customer needs.

Please visit www.merz.com
About the Teijin Group
Teijin (TSE: 3401) is a technology-driven global group offering advanced solutions in thefields of environmental value; safety, security and disaster mitigation; and demographic
change and increased health consciousness. Originally established as Japan's firstrayon manufacturer in 1918, Teijin has evolved into a unique enterprise encompassing
three core business domains: high-performance materials including aramid, carbon
fibers and composites, and also resin and plastic processing, films, polyester fibers andproducts converting; healthcare including pharmaceuticals and home healthcare
equipment for bone/joint, respiratory and cardiovascular/metabolic diseases, nursing
care and pre-symptomatic healthcare; and IT including B2B solutions for medical,
corporate and public systems as well as packaged software and B2C online services for
digital entertainment. Deeply committed to its stakeholders, as expressed in the brandstatement “Human Chemistry, Human Solutions,” Teijin aims to be a company that
supports the society of the future. The group comprises more than 170 companies andemploys some 20,000 people across 20 countries worldwide. Teijin posted consolidated
sales of JPY 836.5 billion (USD 7.7 billion) and total assets of JPY 1,036.4 billion (USD9.5 billion) in the fiscal year that ended on March 31, 2021.

Press Contact
Merz Therapeutics, a business of Merz Pharmaceuticals GmbH
Global Communications+49 69 1503 2129
Agnes.tesch@merz.de
Press Contact
Corporate Communications
Teijin Limited
pr@teijin.co.jp